Joinn Laboratories (China) Co., Ltd. Class A

Joinn Laboratories (China) Co., Ltd. Class A

40.80
CNY
-0.85
(-2.04%)
1.56EPS
31.65P/E
36.94BMarket Cap
Apr 01Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.31
0.4
0.45
0.52
0.59
0.66
1.04
1.74
2.1
3.04
3.17
2.72
2.23
2.53
Basic EPS, GAAP
0.05
0.11
0.11
0.11
0.15
0.17
0.3
0.51
0.77
1.44
0.53
0.1
0.4
1.56
Free Cash Flow per Basic Share
- -
0.09
0.14
0.14
0.19
0.07
0.03
0.45
0.62
0.93
0.57
0.09
0.4
- -
Dividend per Share
0.01
0.03
0.01
- -
- -
0.04
0.06
0.09
0.13
0.18
0.29
0.16
0.03
0.02
Book Value per Share
0.26
0.34
0.45
0.56
0.91
1.06
1.37
1.96
9.55
10.91
11.04
10.78
11.11
12.23
Tangible Book Value per Share
0.17
0.25
0.36
0.47
0.84
0.98
0.98
1.56
9.2
10.33
10.47
10.2
10.65
11.79
Basic Weighted Avg Shares
466
461
463
463
514
621
617
617
723
746
749
741
745
736
Sales/Revenue/Turnover
144
185
207
242
301
409
639
1,076
1,517
2,268
2,376
2,018
1,658
1,861
Operating Margin (%)
17.77
27.77
23.25
22.1
30.66
28.29
31.17
28.05
29.8
31.62
26.66
8.98
-2.54
3.05
Depreciation Expense
- -
21
24
27
26
29
42
61
96
121
130
130
144
- -
Net Income, GAAP
22
49
49
52
76
108
187
315
557
1,074
397
74
298
1,147
Effective Tax Rate (%)
15.46
21.64
14.75
15.27
18.17
15.38
13.39
13.02
13.33
13.45
22.76
32.95
11.75
8.69
Profit Margin (%)
15.5
26.51
23.8
21.38
25.37
26.5
29.21
29.28
36.76
47.37
16.71
3.67
17.97
61.64
Working Capital
-118
-79
-41
-11
286
284
174
408
4,600
4,084
5,655
3,921
4,102
4,780
LT Debt
- -
- -
- -
- -
- -
- -
9
75
69
60
42
22
1
16
Total Equity
122
159
208
260
558
654
850
1,222
7,144
8,191
8,281
8,079
8,325
9,166
Return on Invested Capital (%)
7.53
17.47
18.44
18.72
18.53
17.47
24.3
28.38
12.97
13.61
4.69
0.85
3.62
13.2
Return on Capital (%)
13.65
26.4
24.11
22.07
18.7
17.9
24.49
29.01
13.14
13.9
4.87
0.97
3.63
13.23
Return on Common Equity (%)
20.19
34.96
26.82
22.1
18.71
17.89
24.84
30.4
13.34
14.02
4.82
0.91
3.63
13.28

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
25
20
21
LT Borrowings
- -
- -
- -
LT Finance Leases
12
12
16
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
749
749
749
Market Capitalization
25,628
28,640
36,943

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
5,067
6,503
6,712
Cash, Cash Equivalents & STI
2,494
2,382
2,539
Accounts Receivable, Net
184
168
170
Inventories
1,563
1,862
1,952
Total Current Liabilities
1,262
1,605
1,932
Payables & Accruals
- -
- -
- -
ST Debt
25
20
21
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
73.13%
100.22%
3.05%
Free Cash Flow
148.31%
65.3%
332.81%
Net Income, GAAP
56.32%
65.47%
302.08%
Sales/Revenue/Turnover
26.43%
12.47%
-17.87%
Total Cash Common Dividend
11,952.48%
9.08%
-81.29%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
325
525
486
683
2,018
2025
287
381
- -
673
1,658
2026
316
388
484
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.36
0.14
0.13
0.19
0.1
2025
0.05
0.03
- -
0.3
0.4
2026
0.32
0.69
0.25
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.16
2025
- -
- -
- -
- -
0.03
2026
- -
- -
0.02
- -
- -

Company Description

CEO
Da Peng Gao
Full Time Employees
2,649
Sector
Health technology
Industry
Biotechnology
Address
A5 Rongjing East Street Beijing BE China 100176
IPO Date
Aug 25, 2017
Business
Joinn Laboratories (China) Co., Ltd. (603127.SS) provides preclinical and non-clinical contract research organization (CRO) services for drug development, including safety evaluation, pharmacology, toxicology, metabolism, and pharmacokinetics studies; clinical trial services encompassing phase I units, bioanalytical testing, and pharmacovigilance; and sales of research models such as rodents, non-human primates, disease models, and experimental animals. The company also offers evaluations for veterinary drugs, pesticides, medical devices, cell-based assays, biologics, gene therapy, and stem cell drugs, with operations spanning China (Beijing headquarters, subsidiaries in Suzhou, Chongqing, Wuzhou, Guangzhou, Shanghai) and the United States (Richmond, CA; Worcester, MA). Founded in 1995 and headquartered at No. 5A Rongjing East Street, Beijing Economic-Technological Development Zone, Joinn serves pharmaceutical, biotechnology, agricultural, and medical device clients globally, holding certifications including CNAS/ILAC-MRA, NMPA, US FDA, OECD GLP, Korean MFDS GLP, and AAALAC accreditation. Recent developments include sustained revenue growth in non-clinical studies (1.92 billion CNY in 2024) and overseas sales expansion (439 million CNY in 2024), alongside H1 2025 profitability recovery after prior challenges, board appointments in January 2025 (Chang Yun Yang, Jing Liang Gu, Fang Tian Ying), and ongoing enhancements to inhalation toxicology and biologics evaluation capabilities.